NKA01
Trauma/Hemorrhagic Shock Resuscitation
Pre-clinicalActive
Key Facts
About NKA Bio
NKA Bio is a private, pre-revenue biotech focused on revolutionizing trauma resuscitation by targeting the body's lethal response to injury, known as shock. Its lead program, NKA01, is an antibody therapy in preclinical development intended for field use by EMS to 'press pause on death' and extend the golden hour for critically injured patients. Founded on pioneering research from Johns Hopkins, the company has secured non-dilutive grant funding, including a $1.25M Air Force SBIR contract, and is preparing to enter clinical trials within 18 months. NKA Bio aims to address the leading cause of death for young adults by bridging the critical gap between injury and definitive surgical care.
View full company profile